Estrogen receptor-a (ERa) and its ligand estradiol (E2) has critical roles in breast cancer growth and are key therapeutic targets. In this study, we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ERa target and a regulator of ERa transcriptional activity. In ERa-positive breast cancer cells, E2 upregulated Adora1 messenger RNA (mRNA) and protein levels, an effect that was reversed by the E2 antagonist ICI 182 780. Small interference RNA ablation of Adora1 in ERapositive cells reduced basal and E2-dependent proliferation, whereas Adora1 over-expression in an ERa-negative cell line induced proliferation. The selective Adora1 antagonist, DPCPX, reduced proliferation, establishing Adora1 as a mediator of E2/ERa-dependent breast cancer growth. Intriguingly, Adora1 ablation decreased both mRNA and protein levels of ERa and, consequently, estrogen-responsive element-dependent ERa transcriptional activity. Moreover, Adora1 ablation decreased binding activity of ERa to the promoter of its target gene TFF1 and led to reduced TFF1 promoter activity and mRNA levels, suggesting that Adora1 is required for full transcriptional activity of ERa on E2 stimulation. Taken together, we showed a short feed-forward loop involving E2, ERa and Adora1 that favors breast cancer growth. These data suggest that Adora1 may represent an important target for therapeutic intervention in hormonedependent breast cancer.
Introduction
Breast cancer is one of the most common malignancies in women, and is the second leading cause of death for women in the United States (Landis et al., 1999) . The mechanisms of breast cancer pathogenesis have been intensively studied, and new treatments targeting this disease have emerged. Drugs such as tamoxifen (Shen et al., 2008; Snoj et al., 2008) , which inhibit the ability of estrogen to activate the estrogen receptor (ER), or aromatase inhibitors (Hayashi and Yamaguchi, 2005; Howell and Buzdar, 2005) , which block aromatase enzyme activity necessary for estrogen production, are used to prevent and treat hormone-responsive breast cancer. Even with aggressive mammographic screening, adjuvant chemotherapy and intensive therapy for existing cancer, however, many of the women who develop breast cancer will die from it. Identification of additional factors that contribute to breast cancer cell proliferation may enhance our understanding of this disease and potentially facilitate the development of novel therapeutic agents.
Estrogen receptor-a (ERa) and its ligand estradiol (E2) has critical roles in breast cancer growth and are important therapeutic targets for this disease (Pettersson and Gustafsson, 2001; Kun et al., 2003; DeNardo et al., 2005) . There is a significant interest in understanding the mechanisms by which ERa signaling is regulated in breast cancer and using this knowledge to develop interventions to that inhibit ERa signaling (Fan et al., 1999; Boulay et al., 2005; Namba et al., 2005; Nonclercq et al., 2007) . We reported earlier that the adenosine A1 receptor (Adora1) is a novel target of ERa (Lin et al., 2007) , the in vivo expression of which significantly correlates with the presence of ERa in breast cancer.
Adora1 is a member of the G protein-coupled receptor superfamily. Adora1 has been actively studied as a potential drug target for the treatment of fetal hypoxia, Pick's disease and for the protection of brain from traumatic brain injury and heart from ischemia-reperfusion injury (Merighi et al., 2003; Kochanek et al., 2006; Morrison et al., 2006; Albasanz et al., 2007; Wendler et al., 2007) . On the basis of these varied roles of Adora1, it has also been suggested that the receptor may act as a potent regulator of normal and tumor cell growth by exerting antiapoptotic and prosurvival effects.
Recently, evidence has emerged that Adora1 is overexpressed in various breast cancer cell lines (Mirza et al., 2005) . We showed earlier that Adora1 is one of many target genes of ERa, and we hypothesized that Adora1 may serve as a mediator of estrogen action in breast cancer growth. In this study, we determined whether Adora1 in turn regulates the transcriptional activity of ERa in breast cancer cells. Our findings suggest that Adora1 may have a dual role as a target and a regulator of ERa in breast cancer cells, and a positive feedback loop between ERa and Adora1 signaling may modulate cancer cell proliferation.
Results
Estrogen upregulates Adora1 mRNA and protein in breast cancer MCF-7 cells Adora1 was identified as a novel target of ERa in our previous study (Lin et al., 2007) . To analyse effect of estrogen on expression of Adora1 in MCF-7 cells, after overnight starvation, various concentrations (10 À5 , 10 À6 , 10 À7 , 10 À8 , 10 À9 , 10 À10 and 10 À11 M) of 17b-E2 were added to the medium for a period of 3 h. Real-time PCR was performed to measure the expression of Adora1. E2 treatment significantly upregulated Adora1 messenger RNA (mRNA), with the largest inductions observed at 10 À5 , 10 À8 , 10 À9 M E2, and relatively lower inductions observed at 10 À6 , 10 À7 , 10 À10 and 10 À11 M E2 (Figure 1a ). To explore the temporal response of Adora1 expression to E2 stimulation, MCF-7 cells were treated with 10 À8 M concentration E2 for 5 days and the level of Adora1 expression was quantified over time by real-time PCR (Figure 1b ). E2-stimulated Adora1 mRNA levels as early as 60 min. Adora1 expression reached eightfold baseline levels at 4 h, after which the magnitude of stimulation decreased gradually and disappeared by 48 h. E2 also induced Adora1 protein levels in a timedependent manner in MCF-7 cells (Figure 1c ). A mild E2 induction of Adora1 protein was noted at 3 h. A robust E2 induction of Adora1 protein was observed at 24 h, which reached a maximum level at 48 h. The E2 antagonist ICI 182 780 reversed E2-stimulated Adora1 expression ( Figure 1d ). These results indicated that E2 upregulates Adora1 mRNA and protein levels in a timeand concentration-dependent manner in MCF-7 breast cancer cells.
Adora1 silencing results in significantly decreased endogenous ERa in MCF-7 cells Upregulation of Adora1 expression in MCF-7 cells on E2 stimulation suggests that Adora1 may have a role in breast cancer progression. As ERa activation is known to promote cell cycle progression (Aitken and Lippman, 1982; Altucci et al., 1996; Osborne and Schiff, 2005) , we examined whether Adora1 modulates ERa function in MCF-7. Specific targeted knockdown of Adora1 mRNA and protein levels was achieved with small interference RNA (siRNA) in MCF-7 cells (Figures 2a and b) .
We monitored Adora1 knockdown efficiency by realtime PCR before downstream experiments. We repeated Adora1 knockdown three times using optimized experimental conditions. Compared with control siRNAtransfected MCF-7 cells, the real-time PCR CT values for Adora1 mRNA in cells transfected with Adora1 siRNA were 4.5-to fivefold higher; real-time PCR D/DCT calculation indicated that Adora1 mRNA levels were significantly lower by 95.6-96.9% in cells transfected with Adora1-siRNA. The average knockdown efficiency was 96.2% ± 0.58 (Po0.01, t-test).
In the presence of Adora1 siRNA, we found that ERa mRNA was downregulated to approximately 60% compared with that in non-silenced cells (Figure 2a ). Silencing of Adora1 also caused a significant decrease of ERa protein level (Figure 2b ). These present results showed that depletion of Adora1 resulted in a marked reduction of both ERa mRNA and protein levels.
To further show that Adora1-dependent signaling regulates ERa levels, we incubated MCF-7 cells in the presence or absence of the Adora1-selective adenosine antagonist DPCPX (10 3 and 10 4 mM) for 12 h and measured ERa protein levels using western analysis. DPCPX is a xanthine derivative compound and highly selective Adora1 ligand (Haleen et al., 1987; Factor et al., 2007) . DPCPX inhibits the effect of adenosine on Adora1 by specifically binding to this receptor. DPCPX treatment significantly abolished ERa protein ( Figure 2c ). This verifies the conclusion that Adora1 knockdown or inhibition of its signaling pathway ablates ERa.
Silencing of adenosine A1 receptor is associated with a decrease in breast cancer cell proliferation It has been shown that the Adora1 gene is located proximally to an ERa binding site and that its expression is induced by E2 (Lin et al., 2007) . In this study, we showed that depletion of Adora1 resulted in significantly decreased mRNA and protein level of ERa ( Figure 2 ). As ERa activation and its signaling are critical for cell proliferation (Chalbos et al., 1982; Laganiere et al., 2005; Fu et al., 2006) , we tested the possibility that Adora1 modulates ERa-mediated cell proliferation in breast cancer pathobiology. MCF-7 cells were cultured in steroid-deprived medium for 3 days, and siRNA against Adora1 or control siRNA was transiently transfected into the cells for 48 h followed by 20-to 24-h treatment with E2 or vehicle. We confirmed Adora1 knockdown by immunoblot ( Figure 3a ). As shown in Figure 3b , knockdown of Adora1 in MCF-7 cells treated with or without E2 resulted in significantly decreased cell proliferation (24.9 and 14.8%, respectively) compared with cells transfected with control siRNA (14.0 and 9.5%, respectively). We confirmed this result by quantification of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation and prognosis (23, 24), by immunoblot. Knockdown of Adora1 decreased cell proliferation as shown specifically by a decrease in PCNA immunostaining (Figure 3c ). The lowest level of PCNA was observed in Adora1-depleted cells incubated with vehicle. In E2-treated cells, silencing of Adora1 resulted in remarkable decrease in PCNA level compared with that in the non-silenced MCF-7 cells. Data obtained from quantification of PCNA corroborated those from the MTT assay in Figure 3b . To further show a role of Adora1 in Adora1 regulates the transcriptional activity of ERa Z Lin et al cell proliferation, we inhibited the effect of adenosine on this receptor using the Adora1-selective antagonist, DPCPX, which also attenuated in MCF-7 breast cancer cell proliferation ( Figure 3d ) and E2-induced cell proliferation by 2.46-fold ( Figure 3e ). These results indicate that depletion of Adora1 or inhibition of the downstream signaling pathway significantly decreased mRNA and protein levels of ERa, and inhibited E2-induced cell proliferation in MCF-7 cells.
Over-expression of Adora1 is associated with an increase in proliferation of ERa negative MDA-MB-231 breast cancer cells The inhibitory effect of Adora1 depletion on cell proliferation in ER-positive MCF-7 cell prompted us to analyse whether over-expression of a full-length Adora1 complementary DNA in ER-negative MDA-MB-231 cells could stimulate cell proliferation. Overexpression of Adora1 increased cell proliferation as shown in Figure 3f specifically by an increase in viable cells measured by MTT assay and by PCNA immunostaining, compared with cells transfected with an empty pcDNA 3.1 vector (control). Transfection with the Adora1 expression vector significantly increased the viable cell numbers. These results further support our conclusion that Adora1 is a mediator of breast cancer cell growth.
Targeted knockdown of Adora1 inhibits ERa transcriptional activity
To determine whether Adora1 mediates ERa transcription, we examined the transcriptional activity of , 2, 3, 4, 6, 8, 10, 24, 48, 72, 96 or 120 h; (c) E2 (10 À8 M) or vehicle (EtOH) for 0, 1, 3, 4, 8, 24, 48 h; or (d) E2 (10 À8 M), ICI 182 780 (10 À6 M) or vehicle for 3 h. Cells were harvested, total RNA was isolated, and messenger RNA (mRNA) levels of adenosine A1 receptor (Adora1) at each dose and time points were measured by real-time PCR and normalized by GAPDH. Data are the average of three replicates ± s.d. *Po0.01 determined by t-test. Adora1 protein levels were measured by immunoblot. b-actin was used as a loading control.
Adora1 regulates the transcriptional activity of ERa Z Lin et al endogenous ERa on an ERE-dependent reporter construct in MCF-7 and T47D cells after siRNA silencing of Adora1. Specific targeted knockdown of Adora1 protein was achieved (Figure 4a in MCF-7 cell and Figure 4c in T47D). Breast cancer cells were cultured in charcoal-stripped serum for 3 days, followed by transfection of control siRNA or siRNA to Adora1 for 24 h, then co-transfection with an (ERE) 2 -Luc reporter construct for 24 h. Cells were stimulated overnight with E2 or vehicle. As shown in Figure 4 , in both MCF-7 ( Figure 4b ) and T47D (Figure 4d ) cell lines and regardless of the absence or presence of E2, EREmediated transcription was significantly decreased by the addition of siRNAs directed against Adora1 compared with that in non-silenced cells. In agreement with previous data, these results indicate that silencing of Adora1 significantly reduced ERa level leading to reduced transcriptional activity of ERa.
Adora1 silencing decreases binding of ERa to TFF1 promoter and E2-induced expression of the endogenous ERa target gene-TFF1 We examined whether Adora1 has a functional role in transcriptional activation of a known ERa target gene, TFF1, by transfecting siRNAs directed against Adora1 in MCF-7 cells. As shown in Figure 5a , knockdown of Adora1 expression resulted in a marked reduction of E2-induced recruitment of ERa to the TFF1 promoter. This result suggested that Adora1 might be required for ERa transactivation of E2-responsive gene. As shown in Figure 5b , a TFF1-luciferase promoter construct was poorly induced by E2 in Adora1 silenced MCF-7 cells compared with Adora1 non-silenced MCF-7 cells. Thus, introduction of siRNAs directed against Adora1 con-siderably decreased the ability of ERa to stimulate transcription from the TFF1 promoter. Next we analysed whether the presence of Adora1 is required for binding of ERa to the TFF1 promoter. To determine more directly whether Adora1 is involved in regulating expression of ERa target, we examined the effect of inhibiting Adora1 expression on E2-induced expression of ERa target gene, TFF1. The presence of the siRNAs significantly reduced the ability of E2 to stimulate the expression of a selected ERa target, TFF1 (Figure 5c ), but not the non-target siRNA. These results suggest that Adora1 is required for the full ERa transcription activity. It also, in agreement with the luciferase assay with ERE-dependent construct performed in MCF-7 cells, confirms the involvement of Adora1 in the regulation of ERa target gene expression. These results show that Adora1 has an important role in ERa binding and transcriptional activity and the necessity of Adora1 for full ligand-dependent activity of ERa.
Discussion
In this study, we provide evidence for a novel dual role of the Adora1 as a target and a regulator of E2/ERa action in breast cancer. We show that E2 upregulates Adora1 mRNA and protein level, and that the inhibition of Adora1 either by RNAi or its selective antagonist attenuated MCF-7 breast cancer cell proliferation by abolishing ERa and its E2-dependent transcriptional activity. These findings suggest the existence of a short feed-forward loop involving E2, ERa and Adora1 that modulate breast cancer cell proliferation. Studies have revealed that the ERa gene is regulated at the levels of activity of its transcription factor, such as AP2 (McPherson et al., 1997) , transcribed ERa mRNA stability (Kenealy et al., 2000) , and its protein degradation (Alao et al., 2004) . In this study, we found that ablation of Adora1 resulted in markedly decreased ERa mRNA and protein levels; this may represent a novel mechanism, by which Adora1 decrease the binding of transcription factor, such as AP2 to ERa promoter regions, which result in decreased ERa mRNA transcribed and protein translated, and therefore the reduced the binding of ERa to its target genes. Although our findings do not exclude the possibility that loss of Adora1 may shorten the half-life of ERa message or enhance ubiquitin degradation of ERa, others have suggested that suppression of ERa expression, rather than decreased stability of ERa mRNA and protein, is a more likely mechanism by which ERa activity is regulated (Lu et al., 2003; Huang et al., 2006) . The ERa gene contains multiple promoters, some of which are as far as 150-kb upstream of the primary transcriptional start site (Reid et al., 2002) . Only a few transcription factors are known to regulate ERa expression (McPherson et al., 2007) , including AP2. Additional experiments are needed to elucidate the mechanism of ERa downregulation by ablation of Adora1.
How Adora1 exerts of its effects on ERa function in the proliferation of human breast cancer MCF-7 cells is also unclear. It is possible that Adora1 cooperates with ERa in regulating E2-dependent cell proliferation. E2 treatment significantly increased expression of Adora1, indicating that Adora1 upregulation, mediated by ligand-activated ERa, may be involved in breast cancer initiation and progression. It is possible that ERamediated E2 signaling might cross-talk with Adora1mediated signaling through an unknown mechanism that regulates transcription and proliferation.
In this study, we identified Adora1 as being essential for ERa-stimulated TFF1 promoter activity and expression. TFF1 is a prototypic gene representing a subset of ERa target promoters, and has been shown to have an important role in breast cancer cell proliferation (Prest et al., 2002) . The results of this study not only presents a new paradigm in the control of estrogen action but a mechanism by which Adora1 (Carroll et al., 2005) . The ablation of Adora1 resulted in decrease of ERa and E2-induced ERa transcriptional activity. As a consequence, ERa- 
Luciferase activity
Control siRNA Adora1 siRNA TFF1-Luc pGL4 E2(10 -8 M) (c) Adora1 silencing results in significantly decreased TFF1 expression. MCF-7 cells were transfected either with control or Adora1 siRNA (100 nM) and treated with vehicle or E2 (10 À8 M) overnight. Cells were then lysed, total RNA was extracted and mRNA levels of Adora1 were measured by real-time PCR and normalized to GAPDH. Data represent the average of three replicates ± s.d. (*Po0.5 determined by t-test).
Adora1 regulates the transcriptional activity of ERa Z Lin et al mediated breast cancer cell proliferation was therefore reduced.
In this study, we showed the inhibitory effect of DPCPX, an Adora1-selective adenosine antagonist, on ERa signaling. DPCPX inhibits the effect of adenosine on Adora1 by specifically binding to this receptor. DPCPX was used under in vitro and in vivo conditions to evaluate the role of Adora1 in the lungs (Factor et al., 2007) , brain (Ilie et al., 2009) , gut (Brunsden and Grundy, 1999) , heart and kidney (Moosavi et al., 2009) . Preliminary experiments revealed that antagonism of Adora1 activity result in a reduction in ERK1/2 phosphorylation (data not shown), which is critical for E2-mediated cell growth (Keshamouni et al., 2002) . It has been shown that ERK phosphorylation is associated with increased ERE-mediated transcription in ovarian cancer (Bourguignon et al., 2005) and breast cancer (Kuske et al., 2006) . In this study, we found that depletion of Adora1 caused a decrease in both ERa mRNA and protein levels in MCF-7 breast cancer cell line. In vivo, we showed earlier a significant positive correlation between ERa and Adora1 mRNA levels in ERa þ breast cancer tissues (Lin et al., 2007) . Our data may have clinical implications in that the ablation or antagonism of Adora1 appears to inhibit ERa-mediated tumor cell growth. Our data suggest that the blockade of signaling pathways downstream of Adora1 may have a protective effect against tumor development and that the Adora1 pathway may represent an important target for therapeutic intervention in hormone-dependent breast cancer.
Materials and methods
Cell lines MCF-7, T47D and MDA-MB-231 cells (American Type Culture Collection, ATCC, Manassas, VA, USA) were maintained in minimum essential medium ( Invitrogen, Carlsbad, CA, USA) containing penicillin (25 U/ml), streptomycin (25 U/ml), insulin (0.01 mg/ml) and 10% fetal bovine serum. When indicated, the cells were cultured with charcoalstripped serum for 3 days. After overnight starvation, cells were treated with E2 (10 À8 M), ICI 182 780 or vehicle for the indicated times. Cells were then collected and subjected to realtime PCR analysis, immunoblot, luciferase activity assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Invitrogen).
Reagents
E2 and ICI 182 780 (ICI) were obtained from the Sigma (St Louis, MO, USA). MTT assay kit was from Invitrogen. Final concentrations of 10 À8 M and 10 À6 of E2 and ICI were diluted into culture medium at the indicated times.
Real-time PCR
Total RNA was extracted from cells, treated with DNase I, and reverse transcribed using random hexamers and Super-Script III reverse transcriptase enzyme (Invitrogen). Real-time PCR was carried out with SYBR Green or Taqman Real-Time Core Reagents (Applied Biosystems, ABI, Foster City, CA, USA) on the ABI 7000 or 7900 HT Sequence Detection Systems. Primers and probes for quantification of Adora1 and ERa were purchased from ABI. Levels of expression were normalized to the GAPDH gene.
Knock-down of Adora1 by small interference RNA RNA interference was carried out by using SMARTpool siRNA designed against Adora1 and control (nontargeting) siRNA as a negative control (Dharmacon, Lafayette, CO, USA). The target sequences of siRNA oligonucleotides against Adora1 were: (1) 5 0 -GGAGGAGCCUGGAGUGUAA-3 0 ; (2) 5 0 -GGUAGGUGCUGGCCUCAAA-3 0 ; (3) 5 0 -GGAGUCUG CUUGUCUUAGA-3 0 ; and (4) 5 0 -CAAGAUCCCUCUCCG GUAC-3 0 . To verify that these oligonucleotide sequences in the Adora1 siRNA pool specifically targeted Adora1 but not ERa mRNA, we aligned the four Adora1 siRNA oligonucleotide sequences with ERa mRNA (Locus number: NM_000125 from National Center for Biotechnology Information DNA database) by Blast alignment from National Center for Biotechnology Information. Alignment of these sequences to ERa mRNA did not show any homology, indicating that these siRNA oligonucleotides do not target ERa mRNA. After 3 days of culture in minimum essential medium containing 10% charcoal-stripped calf serum, siRNA against Adora1 or control siRNA at a final concentration of 100 nmol/l was transfected into the MCF-7 cells for 48 h. The cells were then stimulated with E2 (10 nM) or vehicle for 20-24 h and harvested for analysis.
Plasmid constructs
To generate the estrogen-responsive luciferase reporter construct (ERE) 2 -Luc for transient transfection assays in breast cancer cell lines, a synthesized oligo contained consensus ERE site (underlined) (5 0 -GTACCAGGTCACAGTGACCTGAT CAGCTAGTCAGGTCACAGTGACCTTCGTAC-3 0 ) was ligated into the blunted HindIII site of the pGL4.10 (luc 2) vector (Promega, Madison, WI, USA). The promoter region of the TFF1 gene from nucleotides À428 to À332 (Nunez et al., 1989) was amplified and then ligated into PGL4.10 (luc 2). The plasmid constructs above were confirmed by sequencing.
To analyse inducible effect of Adora1 expression on cell proliferation, a full-length Adora1 complementary DNA was cloned into the pcDNA3.1 vector (Invitrogen). The complementary DNA has been amplified after reverse transcription of Adora1 mRNA from MCF-7 cells. We used the following primers for PCR amplification: forward primer, 5 0 -CACCA TGCCGCCCTCCATCT-3 0 and reverse primer, 5 0 -GTCAT CAGGCCTCTCTTCTGG-3 0 . The PCR profile was 3 min at 94 1C, followed by 40 cycles of 30 s at 94 1C, 30 s at 60 1C and 1 min at 72 1C, and a final extension of 7 min at 72 1C. The amplified fragments were analysed on a 1% agarose gel. The PCR fragments were directly cloned into the pcDNA3.1 expression vector (Invitrogen) as described in the manufacturer's protocol and sequenced to check its fidelity.
Luciferase assay
Hormone-depleted breast cancer cells were transfected with Adora1 or control siRNA (final concentration 100 nM, Dharmacon) using Fugene HD transfection reagent (Roche, Indianapolis, IN, USA) for 24 h. The cells were then cotransfected with (ERE) 2 -Luc plasmid or empty vector for 24 h followed by treatment with or without E2 (10 À8 M) overnight. Cells were then harvested and assayed for luciferase and pCMVb-gal (a constitutive b-galactosidase expression vector used to normalize transfection efficiency) activities (Promega). Over-expression of Adora1 gene in MDA-MB-231 cells Hormone-depleted MDA-MB-231 cells were transfected with Adora1 expression plasmid or pcDNA3.1 empty vector using Fugene HD transfection reagent for 48 h. Adora1 expression vector or pcDNA3.1 empty plasmid (24 mg) was transfected to cells cultured in 10-cm dishes, as described in the manufacturer's protocol. Cells were then harvested at 48 h after transfection and over-expression efficiency was verified by western blot. Cell proliferations were measured by MTT assay and by immunoblot of PCNA as described below.
Chromatin immunoprecipitation
After knock-down of Adora1 with siRNA, cells were subjected to chromatin immunoprecipitation with ERa based on a protocol described earlier (Lin et al., 2007) . The immunoprecipitated and input DNA samples were assayed for binding to the TFF1 promoter region. The primers were: forward primer, 5 0 -GGCCATCTCTCACTATGAATCACTTCTGC-3 0 ; reverse primer, 5 0 -GGCAGGCTCTGTTTGCTTAAAGA GCG-3 0 . For PCR, 1 ml of purified DNA was used in the following PCR profile: 3 min at 94 1C, followed by 35 cycles of 30 s at 94 1C, 30 s at 60 1C and 30 s at 72 1C; and a final extension of 7 min at 72 1C. The amplified PCR products were analysed on a 1% agarose gel.
Cell proliferation assay
Cell proliferation was measured by immunoblot of PCNA or by used the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay (Invitrogen). After transfection and treatment, the MTT reagent was applied for 4 h and the resulting formazan crystals were dissolved overnight. The result was measured on the plate reader set to record absorbance at 570 nm.
Protein extraction and immunoblotting
Protein was extracted from treated cells and immunoblot was performed by using ERa (Millipore, Billerica, MA, USA), PCNA, or b-actin (loading control) antibodies based on a standard protocol as follows. Aliquots of 20 mg of total protein were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose membrane (Millipore). The membrane was blocked for 1 h at room temperature with 5% milk in TBS followed by hybridization with primary antibodies at a dilution of 1:1000 directed against the following: A1 adenosine receptor (Adora1, rabbit polyclonal, EMD), ERa (rabbit monoclonal, Millipore); PCNA (mouse monoclonal, Millipore); b-actin (mouse monoclonal, 1:10 000 dilution, Sigma). After washing, the membrane was then incubated for 1 h at room temperature with appropriate horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology, Danvers, MA, USA) at a dilution of 1:4000. Immunoreactive bands were detected by a chemiluminescence (Pierce, Rockford, IL, USA) and visualized by autoradiography.
